Access our latest resources—including publications about our science, recent media, and conference presentations.

Oct 2022 | From Ikena Oncology

IK-930, a Novel TEAD-inhibitor, Overcomes Hippo/YAP-mediated Adaptive Response to MEK and EGFR-targeted Therapies

Mihir Rajurkar, Ph.D. | EORTC-NCI-AACR 2022

May 2022 | From Ikena Oncology

Hippo Pathway Relationship to RAS / EGFR Signaling; Therapeutic Potential

Jeffrey Ecsedy, PhD | Hippo Pathway Targeted Drug Development Summit

Apr 2022 | From the Media

Aadi, SOTIO and Ikena Target Cancer-Causing Mutations at AACR

BioSpace | IK-930

Scroll to Top